Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates

Financial Performance - Tarsus Pharmaceuticals reported a quarterly loss of $0.2 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.19, but an improvement from a loss of $0.6 per share a year ago, indicating a year-over-year improvement [1] - The company posted revenues of $151.67 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 4.63% and significantly up from $66.41 million in the same quarter last year [2] - Over the last four quarters, Tarsus has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Tarsus Pharmaceuticals shares have declined approximately 18.7% since the beginning of the year, contrasting with the S&P 500's gain of 0.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.05 on revenues of $146.92 million, and for the current fiscal year, it is $1.22 on revenues of $675.12 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Tarsus belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]